Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression. METHODS: In 219 cognitively unimpaired and 12...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Alzheimers Res Ther
Autori principali: Guo, Tengfei, Korman, Deniz, La Joie, Renaud, Shaw, Leslie M., Trojanowski, John Q., Jagust, William J., Landau, Susan M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7429887/
https://ncbi.nlm.nih.gov/pubmed/32799929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00665-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi